Volume 20 No 9 (2022)
 Download PDF
To evaluate Efficacy and Safety for Management of Neuropathic Pain with Gabapentin, Pregabalin and Amitriptyline”
Dr Nitin Kumar Singh, Dr Himanshu Jain, Dr Manisha Upadhyay, Dr Archana Singh
Abstract
Neuropathic pain caused by a lesion or disease of the somatosensory system. The somatosensory system allows for the perception of touch, pressure, pain, temperature, position, movement and vibration. Gabapentin is an anticonvulsive medication that originally saw use as a muscle relaxer and anti-spasmodic medication. It is also useful in certain types of neural pain control. Pregabalin (PGB) is a newer generation gabapentinoid which followed the use of gabapentin (GBP). This was secondary to limited efficacy in epilepsy as an adjuvant adjuvant antiepileptic drug, but also because of a series of case reports describing the benefits of gabapentin in the treatment of neuropathic pain (NeP). Amitriptyline is FDA approved medication to treat depression in adults. The Non-FDA approved indications are anxiety, post-traumatic stress disorder, insomnia, chronic pain (diabetic neuropathy, fibromyalgia).
Keywords
Amitriptyline, Pregabalin, Gabapentine, Neuropathic pain
Copyright
Copyright © Neuroquantology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the Neuroquantology are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJECSE right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.